Skip to content
Search Library
thumbnail

The FDA has approved a new medication for the treatment of equine protozoal myeloencephalitis (EPM). The medication, a drug combination called ReBalance, is produced by Pegasus Laboratories.

ReBalance combines two antimicrobial agents that have previously been used to treat EPM by inhibiting folic acid synthesis. The new product is said to be less expensive than using the two separate preparations to obtain the same antiprotozoal effect.

ReBalance is available through veterinary distributors.

X

Subscribe to Equinews and get the latest equine nutrition and health news delivered to your inbox. Sign up for free now!